“…Currently, the use of biomaterials in various applications such as orthognathic surgery has driven the development of techniques using allografts, autologous implants and demineralized bone matrix (DBM), However, according to the American Association of Tissue Banks (AATB), deregulation has led to problems, because bone must be harvested from the patient and/or corpse, causing risks of infections, morbidity and potential legal issues [1][2][3][4][5][6]. A base biomaterial Mg -25 wt% Ca -5 wt% Zn that can be used as a scaffold for the fractured bone to recover, avoiding tissue laceration and re-operation, can provide a higher healing rate without the risks associated with the primary procedure [7][8][9][10]. For applications where a scaffold is required as a complement to manage a fracture, the proposal of a porous scaffold made of Mg -25 wt% Ca -5 wt% Zn has become an interesting option [10][11][12], because the FDA has determined that the products contained within a human demineralized bone matrix (DBM), do not comply with the provisions of Section 361 of the public health service law, mainly because they are not sterilizing agents [13].…”